Quinazolinone–diarylpyrazole hybrids as dual EGFR/COX-2 inhibitors: antiproliferative, mechanistic, and in silico studies
7f is identified as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects, consistent with its experimentally observed dual inhibitory activity.